Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Inlyta (axitinib by Quarter
Inlyta (axitinib — renal cell carcinoma) — U.S. revenues ($M) ($M)
Pfizer Inlyta (axitinib: $114M in Q2 2026, down 13.6% from a year earlier.
Latest, Q2 2026
114
Period ended Jun 28, 2026
Change on a year earlier
-13.6%
132 in Q2 2025
History
39 quarters
Since Q4 2016
Sources
35
Documents cited below
Where the Q2 2026 figure comes from
“|| Inlyta | 218 | 243 | (10%) | (12%) | 114 | 132 | (14%) | 105 | 111 | (5%) | (10%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up inlyta (axitinib
Cite this data
StockData. (2026). Pfizer Inlyta (axitinib ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/inlyta-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.